klhl38 Antibody

What is KLHL38 and why is it significant in cancer research?

KLHL38 is a member of the Kelch-like (KLHL) protein family, containing a BTB domain, a back domain, and six kelch domains . It has gained significance in cancer research due to its overexpression in non-small cell lung cancer (NSCLC) and its correlation with clinicopathological parameters including tumor size, lymph node metastasis, and pathological tumor-node-metastasis stage . Research has demonstrated that KLHL38 promotes cancer progression through activation of the Akt signaling pathway by facilitating PTEN ubiquitination and degradation . This mechanism makes KLHL38 a valuable potential prognostic biomarker and therapeutic target, particularly for NSCLC.

What is the cellular localization of KLHL38?

Immunocytochemical analysis has revealed that KLHL38 is localized in both the cytoplasm and nuclei of various cell types, including A549, H1299, H460, H661, and SK-MES-1 lung cancer cell lines as well as normal bronchial epithelial HBE cells . This dual localization suggests that KLHL38 may have functions in both cellular compartments, potentially regulating different molecular processes depending on its subcellular position . Understanding this localization pattern is crucial for proper antibody selection and experimental design when studying KLHL38.

How does KLHL38 expression differ between normal and cancerous tissues?

KLHL38 shows significant differential expression between normal and cancerous tissues. RNA extraction and real-time PCR analysis of 43 matched pairs of clinical lung cancer and normal tissue samples revealed significantly higher KLHL38 levels in cancers compared to matched normal tissues . Western blotting confirmed elevated KLHL38 levels in 14 of 16 lung cancer tissues analyzed versus matched normal tissues . Immunohistochemical results further demonstrated KLHL38 overexpression in clinical lung cancer tissues, while normal bronchi and alveoli showed minimal KLHL38 expression . This expression pattern supports the potential role of KLHL38 as a diagnostic biomarker.

What are the recommended methods for detecting KLHL38 expression in tissue samples?

For comprehensive KLHL38 expression analysis in tissue samples, multiple complementary techniques are recommended:

For clinical samples, a combination of IHC for localization and qRT-PCR for quantitative assessment is often optimal . When validating new findings, comparing results across multiple detection methods is strongly recommended to ensure consistency and reliability.

How can KLHL38 expression be effectively modulated in experimental settings?

To modulate KLHL38 expression in experimental models, several approaches have proven effective:

The research successfully employed both transient transfection approaches for in vitro studies and stable transfection with G418 selection for in vivo xenograft models . For the latter, A549 and SK-MES-1 cells were stably transfected using G418 and the relevant plasmids, leading to significant effects on xenograft tumor volume and weight . When designing experiments, researchers should select appropriate control conditions, including empty vector controls for overexpression studies and non-targeting siRNA for knockdown experiments.

What are the best practices for immunoprecipitation with KLHL38 antibody?

For successful immunoprecipitation (IP) of KLHL38 and its interaction partners:

• Lysis buffer selection: Use a buffer that preserves protein-protein interactions while effectively lysing cells

• Pre-clearing: Incubate lysates with protein A/G beads to reduce non-specific binding

• Antibody incubation: Use optimized amounts of validated anti-KLHL38 antibody

• Controls: Include IgG control and input samples to assess specificity

• Washing conditions: Use stringent washing to reduce background while preserving specific interactions

• Confirmation: Validate interactions through reverse IP and additional techniques

For studying KLHL38-PTEN interactions specifically, co-immunoprecipitation experiments have successfully demonstrated that KLHL38 directly interacts with PTEN in lung cancer cells . This approach revealed that KLHL38 promotes PTEN ubiquitination, a key mechanism in its oncogenic function .

How do you interpret contradictory KLHL38 expression data between different techniques?

When faced with contradictory KLHL38 expression data across different detection methods:

• Evaluate what each technique actually measures:

  • qRT-PCR measures mRNA levels

  • Western blotting and IHC measure protein levels

  • The study showed that KLHL38 regulates PTEN at the protein level but not at the mRNA level, indicating potential post-transcriptional regulation

• Consider technique-specific limitations:

  • IHC: Fixation artifacts, antibody specificity, semi-quantitative nature

  • Western blotting: Sample preparation differences, loading control issues

  • qRT-PCR: RNA quality, primer specificity, reference gene stability

• Assess biological variables:

  • Heterogeneity within tumor samples

  • Different stages of disease progression

  • Patient characteristics (age, sex, ethnicity)

The published research noted a discrepancy between their clinical data and TCGA database regarding survival correlation with KLHL38 expression, suggesting potential differences based on racial ethnicity of patient populations . This highlights the importance of considering population-specific effects when interpreting conflicting data.

What controls should be included when studying KLHL38 in cancer models?

Comprehensive control strategies for KLHL38 research in cancer models include:

The research successfully employed pathway inhibitors (HY-128693, AKT VIII) to verify KLHL38's role in the PTEN/Akt pathway, demonstrating the importance of mechanistic controls . These inhibitors helped establish that KLHL38 promotes cancer progression specifically through Akt pathway activation.

What are common pitfalls in KLHL38 immunohistochemistry data interpretation?

Key challenges and solutions in KLHL38 IHC interpretation include:

• Heterogeneous expression:

  • Evaluate multiple tumor regions

  • Score hotspots and average areas separately

  • Use digital pathology for whole-slide quantification

• Subcellular localization variations:

  • The study found KLHL38 in both cytoplasm and nuclei

  • Score nuclear and cytoplasmic staining independently

  • Consider differential biological significance of each pattern

• Scoring subjectivity:

  • Use multiple independent pathologists

  • Implement digital image analysis

  • Establish clear scoring criteria before evaluation

• Threshold determination:

  • Statistical approaches (median, ROC curve analysis)

  • Correlation with functional outcomes

  • Clinically relevant cutpoints

The research successfully correlated KLHL38 expression with multiple clinicopathological parameters, including tumor size, lymph node metastasis, and p-TNM stage, providing a roadmap for meaningful IHC interpretation .

What are the mechanisms of KLHL38-mediated PTEN ubiquitination?

The molecular mechanisms of KLHL38-mediated PTEN ubiquitination include:

• Direct protein interaction:

  • Co-immunoprecipitation experiments confirmed direct interaction between KLHL38 and PTEN

  • This physical interaction is prerequisite for ubiquitination

• E3 ubiquitin ligase complex formation:

  • KLHL family proteins typically function as substrate adaptors for Cullin-RING ligases

  • BTB domain likely mediates interaction with Cullin scaffold proteins

  • Kelch domains likely involved in PTEN substrate recognition

• Ubiquitin transfer process:

  • Promotes conjugation of HA-ubiquitin to PTEN

  • Leads to polyubiquitination and subsequent proteasomal degradation

  • MG132 (26S proteasome inhibitor) treatment allowed detection of ubiquitinated forms

• Specificity mechanisms:

  • KLHL38 affects PTEN at protein level but not mRNA level

  • Experiments showed unaltered PTEN mRNA expression regardless of KLHL38 status

• Functional consequences:

  • Reduced PTEN protein levels lead to enhanced Akt phosphorylation (p-Akt)

  • PTEN inhibitor (HY-128693) mimicked KLHL38 overexpression effects

  • Ultimately promotes cancer cell proliferation and invasion

The precise ubiquitination sites on PTEN and the specific ubiquitin chain linkage types promoted by KLHL38 remain areas for further investigation.

How does KLHL38 promote cancer cell proliferation and invasion?

KLHL38 promotes cancer cell proliferation, migration, and invasion through several interconnected mechanisms:

• Proliferation pathway activation:

  • Upregulates expression of cyclin D1, cyclin B, and c-myc

  • Downregulates expression of p21 (cell cycle inhibitor)

  • Enhances clone formation in cancer cell lines

• Migration and invasion mechanisms:

  • Upregulates RhoA (cytoskeletal regulator) and MMP9 (matrix metalloproteinase)

  • Downregulates E-cadherin (cell adhesion molecule)

  • Increases secretion of active MMP9 as confirmed by gelatinase analysis

• Signaling pathway modification:

  • Promotes PTEN ubiquitination and degradation

  • Activates Akt signaling through reduced PTEN levels

  • Pathway inhibitor experiments confirmed this mechanism

• In vivo confirmation:

  • Increased xenograft tumor volume and weight

  • Higher lung metastatic rate (5/5 vs. 1/5 for A549 cells)

  • Greater number of lung metastatic nodules

These findings establish a clear mechanistic framework for KLHL38's role in cancer progression, linking molecular interactions to cellular phenotypes and in vivo outcomes.

How can KLHL38 be used as a prognostic biomarker in clinical settings?

Implementation of KLHL38 as a clinical prognostic biomarker would involve:

• Standardized detection methodology:

  • Immunohistochemistry protocol optimization

  • Digital image analysis for consistent scoring

  • Quality control measures and reference standards

• Cutpoint determination:

  • The research found correlation with a 3 cm tumor size cutoff

  • Statistical approaches (ROC curve analysis, outcome-based determination)

  • Validation in independent cohorts

• Integration with existing markers:

  • Combination with established prognostic factors (TNM staging)

  • Multi-marker panels for improved prediction

  • Incorporation into existing prognostic models

• Evidence from research:

  • Positive correlation with tumor size, lymph node metastasis, and p-TNM stage

  • Association with poor prognosis in clinical samples

  • Analysis of 241 NSCLC patients provided substantial statistical power

The research demonstrated significant correlation between KLHL38 expression and clinicopathological parameters in a large cohort of NSCLC patients, providing a strong foundation for biomarker development .

What emerging techniques could enhance KLHL38 protein interaction studies?

Advanced methodologies for investigating KLHL38 protein interactions include:

The research used traditional co-immunoprecipitation to confirm KLHL38-PTEN interaction , but these emerging approaches could provide deeper mechanistic insights, particularly regarding the structural basis of KLHL38-PTEN recognition.

How might KLHL38 function in cancer types beyond NSCLC?

Potential roles of KLHL38 in other cancer types:

• Pathway conservation:

  • PTEN/PI3K/Akt pathway dysregulation is common across multiple cancers

  • KLHL38-mediated PTEN degradation may be relevant in:

    • Breast cancer (high rates of PI3K/Akt activation)

    • Prostate cancer (PTEN loss is common)

    • Glioblastoma (PTEN mutations frequent)

    • Melanoma (Akt pathway activation common)

• Investigative approaches:

  • Pan-cancer analysis of KLHL38 expression (TCGA, ICGC databases)

  • Functional studies in multiple cancer cell lines

  • Correlation with PTEN status across tumor types

  • Animal models of various cancer types with KLHL38 modulation

• Preliminary indications:

  • Database mining showed KLHL38 as potential indicator for prognosis of lung adenocarcinoma and squamous cell carcinoma

  • Kaplan-Meier database suggested KLHL38 may act as tumor promoter in NSCLC

Systematic investigation across multiple cancer types is needed to determine whether KLHL38's oncogenic role is universal or context-dependent.

What is the potential for developing specific KLHL38 inhibitors?

Development strategies for KLHL38-specific inhibitors could include:

• Structural targeting approaches:

  • BTB domain inhibitors to disrupt E3 ligase complex formation

  • Kelch domain inhibitors to prevent PTEN binding

  • Interface disruptors targeting KLHL38-PTEN interaction

• Drug discovery platforms:

  • Structure-based virtual screening

  • Fragment-based drug design

  • High-throughput screening of compound libraries

  • Peptide-based inhibitors mimicking interaction interfaces

• Validation strategies:

  • In vitro ubiquitination assays

  • Cell-based PTEN stabilization readouts

  • Xenograft models (as used in the research)

  • Patient-derived organoids

The research demonstrated that KLHL38 inhibition through siRNA effectively reduced cancer cell proliferation, migration, and invasion , providing proof of concept for therapeutic targeting. Further structural studies of KLHL38 would greatly enhance inhibitor development efforts.

What unknown aspects of KLHL38 biology warrant further investigation?

Critical knowledge gaps and research priorities for KLHL38 include:

• Structural biology:

  • Crystal structure of KLHL38 alone and in complex with PTEN

  • Specific domains involved in PTEN recognition

  • Structural basis for substrate specificity

• Regulatory mechanisms:

  • Factors controlling KLHL38 expression

  • Post-translational modifications affecting KLHL38 function

  • Potential auto-regulatory mechanisms

• Additional substrates:

  • Comprehensive substrate identification beyond PTEN

  • Substrate specificity determinants

  • Tissue-specific target profiles

• Non-ubiquitination functions:

  • Potential scaffolding roles

  • Nuclear functions (given nuclear localization observation)

  • Non-proteolytic ubiquitination activities

The research noted that unlike other KLHL family members where specific domains have been characterized, the particular KLHL38 domains involved in PTEN ubiquitination remain unidentified and warrant further investigation .